- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | ViroGates A/S: ViroGates announces its Interim Report for Q1-Q3 2024: Revenues are disappointing, but strategic refocusing will pave the way for future growth | 59 | GlobeNewswire (Europe) | Company Announcement no. 9/2024 (November 07, 2024)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for the measurement of chronic... ► Artikel lesen | |
| 06.11. | First North Denmark: ViroGates A/S - increase | 144 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North
Growth Market Denmark as per 8 November 2024. New shares are issued due to a
directed issue of new shares.
Name: ... ► Artikel lesen | |
| 21.10. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 21.10.2024 | 299 | Xetra Newsboard | The following instruments on XETRA do have their first trading 21.10.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 21.10.2024
Aktien
1 AU000000ARB5 ARB Corporation Ltd.
2... ► Artikel lesen | |
| 14.10. | ViroGates A/S: ViroGates announces a distribution agreement with suPAR Health and a directed issue of shares to suPAR Remedy LLC | 76 | GlobeNewswire (Europe) | Company Announcement no. 8/2024 (October 14, 2024)
ViroGates announces an agreement with US-based suPAR Health to distribute its blood test for chronic inflammation within the United States. ViroGates... ► Artikel lesen | |
| 15.08. | ViroGates A/S: ViroGates announces its half-year report for H1 2024: Revenue for the first half-year of 2024 falls behind the same period in 2023 due to lower activity among research customers | 37 | GlobeNewswire (Europe) | Company Announcement no. 7/2024 (August 15, 2024)
Inside informationBIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for better... ► Artikel lesen | |
| 17.07. | ViroGates A/S: ViroGates announces revised financial guidance for 2024 | 46 | GlobeNewswire (Europe) | Company Announcement no. 6/2024 (July 17, 2024)
Inside informationBIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for better triaging... ► Artikel lesen | |
| 02.05. | ViroGates A/S: ViroGates announces its Interim Report for Q1, 2024: Quarterly revenue up 14% compared to Q1, 2023 | 38 | GlobeNewswire (Europe) | 2.5.2024 11:20:15 CEST | ViroGates |
Interim information
COMPANY ANNOUNCEMENT - No. 5-2024 - 02 May 2024- Inside information
BIRKERØD, DENMARK - ViroGates A/S announces its Interim Report for the... ► Artikel lesen | |
| 20.12.23 | First North Denmark: ViroGates A/S - increase | 285 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North
Growth Market Denmark as per 21 December 2023. New shares are issued due to
completion of a rights issue.
Name:... ► Artikel lesen | |
| VIROGATES Aktie jetzt für 0€ handeln | |||||
| 24.11.23 | First North Denmark: ViroGates A/S - rights issue - admission to trading of subscription rights | 269 | GlobeNewswire | Subscription rights in ViroGates A/S will be admitted to trading on Nasdaq
First North Growth Market Denmark as per 28 November 2023. As of the same date,
ISIN DK0061030574 (VIRO) will be traded exclusive... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,830 | -0,76 % | KURSEXPLOSION bei Biotech-Aktie! BioNTech, Evotec, Nyxoah | Geht es bei Evotec jetzt doch ganz schnell? Ein Finanzinvestor positioniert sich jedenfalls für eine Übernahme und die Aktie schoss zuletzt kräftig nach oben. Ist damit die Enttäuschung über die Quartalszahlen... ► Artikel lesen | |
| QIAGEN | 39,885 | +2,69 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
VIROGATES A/S gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,47 % bei einem Aktienkurs von 2,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIROGATES A/S finden Sie auf Wallstreet Online.
